<DOC>
	<DOCNO>NCT00433173</DOCNO>
	<brief_summary>The metabolic syndrome medical condition define high level cholesterol blood , high blood pressure , central obesity ( gain fat around region stomach ) , insulin resistance ( body respond less well insulin ) . This state impair insulin resistance lead type 2 diabetes mellitus , one common metabolic disorder U.S . Numerous study show inverse relationship insulin resistance testosterone level men , however , causality establish . This protocol investigate role testosterone modulate insulin sensitivity insulin resistant state metabolic syndrome . The hypothesis testosterone administration improve insulin sensitivity .</brief_summary>
	<brief_title>Insulin Sensitivity Men With Metabolic Syndrome</brief_title>
	<detailed_description>This protocol address impact three month testosterone ( T ) therapy component metabolic syndrome mechanism underlying change insulin sensitivity analyze change body composition , detailed study fat metabolism skeletal muscle . In addition , protocol address role estradiol ( E2 ) mediate effect testosterone insulin sensitivity . Seventy-two subject enrol . Study subject undergo screen visit ass eligibility baseline metabolic assessment perform include fast oral glucose tolerance test ( OGTT ) measure normal glucose insulin metabolism , intravenous glucose tolerance test ( IVGTT ) measure insulin sensitivity , MRI DEXA scan ass muscle body fat distribution , VO2 max test rest metabolic rate , muscle biopsy look muscle affect insulin testosterone ( T ) . Subjects randomized one three 12-week treatment arm , 1 ) Group 1 ( Placebo ) ; 2 ) Group 2 ( Depot GnRH agonist ( Zoladex ) + Testosterone + placebo ) ; 3 ) Group 3 ( Zoladex + Testosterone + aromatase inhibitor ( anastrozole ) ) . The rationale study design follow . Under normal physiological condition , administration T lead concomitant increase estradiol ( E2 ) level due endogenous conversion aromatase enzyme system . Therefore , order understand relative role T E2 insulin sensitivity , one group subject receive T conjunction aromatase inhibitor , anastrozole . At 13 week , entire baseline evaluation include OGTT , IVGTT , rest metabolic rate VO2 max , body composition assessment DEXA MRI , muscle biopsy repeat . Subjects return follow visit four week later measure CBC , T PSA level , ensure level within normal range .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Age 5075 yr Diagnosis metabolic syndrome define American Heart Association/National Heart , Lung , Blood Institute guideline presence three follow : Waist circumference &gt; 102 cm Serum triglycerides &gt; 150 mg/dL HDL cholesterol &lt; 40 mg/dL Blood pressure &gt; 130 mm Hg systolic 85 mm Hg diastolic , treatment antihypertensive Fasting serum glucose &gt; 100 mg/dL Plasma total testosterone level le 300 ng/dL ( 1 SD mean young healthy men ) Stable weight previous three month ( weight change great equal +/10 lb ) Normal TSH , prolactin prostate specific antigen ( PSA ) level ( &lt; 2.5 ng/mL ) New diagnosis type 2 diabetes define ADA criterion : fasting glucose great 126 mg/dL random blood glucose great 200 mg/dL two occasion , oral hypoglycemic agent Contraindication stress test Contraindication MRI scanning ( Central nervous system aneurysm clip ; Implanted neural stimulator ; Implanted cardiac pacemaker defibrillator ; Cochlear implant ; Ocular foreign body ( e.g . metal shaving ) ; Insulin pump ; Metal shrapnel bullet ) History testicular disorder ( i.e . cryptorchidism ) History bleed disorder ( i.e . thrombocytopenia ) baseline hemoglobin level less 12g/dL History metabolic bone disease ( osteoporosis , osteomalacia ) History prostate cancer History sleep apnea ( subject also exclude baseline assessment admit heavy snoring , restless sleep , and/or excessive daytime somnolence ) Symptoms urinary outflow obstruction ( i.e . benign prostatic hypertrophy ) Illicit drug use heavy alcohol use ( &gt; 4 drinks/day ) Allergic disorder Current medication ( must exclude individual take follow medication ) : Testosterone , Cimetidine , Spironolactone , Ketoconazole , Finasteride , DHEA , Androstenedione , Oral steroid , GnRH analog</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>testosterone</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>metabolic disorder</keyword>
</DOC>